Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Nov 2024 According to a Bristol Myers Squibb media release, data from this study will be presented as an Oral Featured Science Presentation on Monday, Nov. 18, 9:57 AM - 10:05 AM, at the American Heart Association (AHA) Annual Scientific Sessions, taking place November 16-18, 2024, in Chicago, Illinois.
02 Sep 2024 Results assessing serial changes in LA strain measures in patients enrolled in the VALOR-HCM trial, presented at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology.
02 Sep 2024 Results assessing effects of mavacamten on heart function in patients with hypertrophic cardiomyopathy (HCM) were published at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com